CR7361A - Peptidos para el tratamiento del cancer asociado al virus papiloma humano (vph) y de otros tumores epiteliales - Google Patents
Peptidos para el tratamiento del cancer asociado al virus papiloma humano (vph) y de otros tumores epitelialesInfo
- Publication number
- CR7361A CR7361A CR7361A CR7361A CR7361A CR 7361 A CR7361 A CR 7361A CR 7361 A CR7361 A CR 7361A CR 7361 A CR7361 A CR 7361A CR 7361 A CR7361 A CR 7361A
- Authority
- CR
- Costa Rica
- Prior art keywords
- peptides
- hpv
- tumors
- treatment
- origin
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000052052 Casein Kinase II Human genes 0.000 abstract 3
- 108010010919 Casein Kinase II Proteins 0.000 abstract 3
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 abstract 3
- 230000026731 phosphorylation Effects 0.000 abstract 2
- 238000006366 phosphorylation reaction Methods 0.000 abstract 2
- 241000341655 Human papillomavirus type 16 Species 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 241001631646 Papillomaviridae Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 231100000590 oncogenic Toxicity 0.000 abstract 1
- 230000002246 oncogenic effect Effects 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se refiere a peptidos utiles para el tratamiento de tumores de origen epitelial y especialmente los asociados a tipos oncogenicos de Virus papiloma (VPH) Identificacion de peptidos cuya estructura permita el bloqueo del dominio de fosforilacion por caseina Kinasa II (CKII) mediante la intetraccion directa con dicho sitio. En la presente invencion se muestran once peptidos de estructura ciclica y secuencia aminoacidica diferente, los cuales inhiben el sitio de fosfoliracion por CKII in vitro, producen citotoxicidad en celulas de carcinoma de cuello uterino humano transformadas en VPH-16 (CasKi) y ademas incrementan la sensibilidad de dichas celulas al efecto citostaticodel interferon.(IFN) Ademas se relaciona con el uso de estos peptidos conjugados o fusionados a otros peptidos y compuestos quimicos de penetracion intracelular asi como on el uso de moleculas mimeticas tanto de origen peptidico como de origen quimico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20010309A CU23225A1 (es) | 2001-12-20 | 2001-12-20 | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR7361A true CR7361A (es) | 2005-02-18 |
Family
ID=40091679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR7361A CR7361A (es) | 2001-12-20 | 2004-06-04 | Peptidos para el tratamiento del cancer asociado al virus papiloma humano (vph) y de otros tumores epiteliales |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7374767B2 (es) |
| EP (2) | EP2383282A1 (es) |
| JP (1) | JP4056476B2 (es) |
| KR (1) | KR100642437B1 (es) |
| CN (1) | CN100368431C (es) |
| AR (1) | AR037825A1 (es) |
| AT (1) | ATE520704T1 (es) |
| AU (1) | AU2002361922B2 (es) |
| BR (1) | BRPI0215213C1 (es) |
| CA (1) | CA2471110C (es) |
| CR (1) | CR7361A (es) |
| CU (1) | CU23225A1 (es) |
| DK (1) | DK1491553T3 (es) |
| DO (1) | DOP2002000548A (es) |
| ES (1) | ES2371239T3 (es) |
| HN (1) | HN2002000377A (es) |
| HR (1) | HRP20040663B1 (es) |
| IL (2) | IL162633A0 (es) |
| IS (1) | IS2906B (es) |
| MA (1) | MA27868A1 (es) |
| MX (1) | MXPA04005832A (es) |
| MY (1) | MY133530A (es) |
| NO (1) | NO333259B1 (es) |
| NZ (1) | NZ534170A (es) |
| PE (1) | PE20030861A1 (es) |
| PT (1) | PT1491553E (es) |
| RU (1) | RU2290410C2 (es) |
| SI (1) | SI1491553T1 (es) |
| TN (1) | TNSN04114A1 (es) |
| UA (1) | UA81403C2 (es) |
| UY (1) | UY27602A1 (es) |
| WO (1) | WO2003054002A1 (es) |
| ZA (1) | ZA200405514B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23225A1 (es) * | 2001-12-20 | 2007-08-30 | Ct Ingenieria Genetica Biotech | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES |
| CU23431B6 (es) * | 2005-05-12 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer |
| GB2433740A (en) * | 2005-12-23 | 2007-07-04 | Rapid Biosensor Systems Ltd | Detection of tuberculosis infection |
| CU23511B6 (es) * | 2006-02-28 | 2010-04-13 | Biorec B V | Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas |
| GB2441131A (en) * | 2006-08-24 | 2008-02-27 | Univ Dundee | Modulation of binding of CK2a to NDPK |
| CN100522992C (zh) * | 2007-02-12 | 2009-08-05 | 中国科学院昆明动物研究所 | 一种环状小肽ba |
| EP2133083A4 (en) * | 2007-03-27 | 2012-02-15 | Taiko Pharmaceutical Co Ltd | THERAPEUTIC FOR SKIN OR MOLECULE INFECTIONS |
| US20110305706A1 (en) | 2009-02-23 | 2011-12-15 | Scott Thomas Brady | Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta |
| CA2755245A1 (en) * | 2009-03-13 | 2010-09-16 | Egen, Inc. | Compositions and methods for the delivery of biologically active rnas |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| CU20200103A7 (es) * | 2020-12-18 | 2022-07-08 | Ct Ingenieria Genetica Biotecnologia | Péptido sintético para la inducción de inmunidad antitumoral y antiviral |
| CU24766B1 (es) | 2021-07-09 | 2025-08-13 | Ct Ingenieria Genetica Biotecnologia | Péptidos lineales que inhiben la fosforilación mediada por ck2 |
| CN118370805B (zh) * | 2024-04-29 | 2025-02-14 | 广州中科佰氏健康产业有限公司 | 一种抑菌妇科凝胶及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE902820A1 (en) | 1989-08-07 | 1991-02-27 | Merck & Co Inc | Peptide inhibitors of human papilloma virus protein binding¹to retinoblastoma gene proteins |
| JPH05310784A (ja) * | 1991-09-04 | 1993-11-22 | Merck & Co Inc | ヒト乳頭腫ウイルスタンパク質と網膜芽細胞腫遺伝子タンパク質との結合のペプチド阻害剤 |
| GB9313556D0 (en) | 1993-07-01 | 1993-08-18 | British Tech Group | Synthetic peptides of human papillomavirus |
| US5625031A (en) * | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
| ATE235509T1 (de) * | 1998-06-30 | 2003-04-15 | Deutsches Krebsforsch | Peptide zur inhibition von hpv e7 proteinen |
| US6641994B2 (en) * | 1999-08-25 | 2003-11-04 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
| AU2001238347A1 (en) * | 2000-02-28 | 2001-09-12 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| CU23225A1 (es) * | 2001-12-20 | 2007-08-30 | Ct Ingenieria Genetica Biotech | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES |
-
2001
- 2001-12-20 CU CU20010309A patent/CU23225A1/es unknown
-
2002
- 2002-04-12 UA UA20040705927A patent/UA81403C2/uk unknown
- 2002-12-04 CA CA2471110A patent/CA2471110C/en not_active Expired - Lifetime
- 2002-12-04 EP EP11168526A patent/EP2383282A1/en not_active Ceased
- 2002-12-04 RU RU2004122084/13A patent/RU2290410C2/ru active
- 2002-12-04 PT PT02796490T patent/PT1491553E/pt unknown
- 2002-12-04 KR KR1020047009771A patent/KR100642437B1/ko not_active Expired - Fee Related
- 2002-12-04 AU AU2002361922A patent/AU2002361922B2/en not_active Ceased
- 2002-12-04 MX MXPA04005832A patent/MXPA04005832A/es active IP Right Grant
- 2002-12-04 BR BRPI0215213A patent/BRPI0215213C1/pt not_active IP Right Cessation
- 2002-12-04 AT AT02796490T patent/ATE520704T1/de active
- 2002-12-04 CN CNB028282698A patent/CN100368431C/zh not_active Expired - Lifetime
- 2002-12-04 DK DK02796490.7T patent/DK1491553T3/da active
- 2002-12-04 IL IL16263302A patent/IL162633A0/xx active IP Right Grant
- 2002-12-04 JP JP2003554718A patent/JP4056476B2/ja not_active Expired - Fee Related
- 2002-12-04 US US10/499,458 patent/US7374767B2/en not_active Expired - Lifetime
- 2002-12-04 SI SI200230967T patent/SI1491553T1/sl unknown
- 2002-12-04 WO PCT/CU2002/000010 patent/WO2003054002A1/es not_active Ceased
- 2002-12-04 HR HRP20040663AA patent/HRP20040663B1/hr not_active IP Right Cessation
- 2002-12-04 EP EP02796490A patent/EP1491553B1/en not_active Expired - Lifetime
- 2002-12-04 ES ES02796490T patent/ES2371239T3/es not_active Expired - Lifetime
- 2002-12-04 NZ NZ534170A patent/NZ534170A/en not_active IP Right Cessation
- 2002-12-11 MY MYPI20024638A patent/MY133530A/en unknown
- 2002-12-13 AR ARP020104844A patent/AR037825A1/es not_active Application Discontinuation
- 2002-12-17 DO DO2002000548A patent/DOP2002000548A/es unknown
- 2002-12-19 HN HN2002000377A patent/HN2002000377A/es unknown
- 2002-12-20 UY UY27602A patent/UY27602A1/es active IP Right Grant
-
2003
- 2003-01-06 PE PE2003000006A patent/PE20030861A1/es not_active Application Discontinuation
-
2004
- 2004-06-04 CR CR7361A patent/CR7361A/es unknown
- 2004-06-15 MA MA27740A patent/MA27868A1/fr unknown
- 2004-06-16 IS IS7320A patent/IS2906B/is unknown
- 2004-06-17 TN TNP2004000114A patent/TNSN04114A1/en unknown
- 2004-06-20 IL IL162633A patent/IL162633A/en not_active IP Right Cessation
- 2004-07-12 ZA ZA2004/05514A patent/ZA200405514B/en unknown
- 2004-07-20 NO NO20043112A patent/NO333259B1/no not_active IP Right Cessation
-
2008
- 2008-04-08 US US12/099,646 patent/US7947287B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23225A1 (es) | PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES | |
| BRPI0816405B8 (pt) | complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação | |
| BR112023014205A2 (pt) | Conjugados anticorpo-fármaco de camptotecina e métodos de uso dos mesmos | |
| CY1105866T1 (el) | Αναλογα ταμανταρινης και διδεμνινης και μεθοδοι παρασκευης και χρησης αυτων | |
| CY1110941T1 (el) | Συνθεση πολυπεπτιου hip/pap για χρηση σε αναζωογονηση ηπατος και για την αποτροπη ηπατικης ανεπαρκειας | |
| CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| CO2023001133A2 (es) | Arn terapéutico para el cáncer positivo para vph | |
| BR112022001866A2 (pt) | Derivados de amida híbridos de anfotericina b | |
| NI200900079A (es) | Novedosos anticuerpos antiproliferación. | |
| CN106749594A (zh) | 包含f1、f3多肽的药物组合物及其在治疗hpv感染疾病中的应用 | |
| BRPI0411085A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de vìrus oncogênicos, e de condições ou distúrbios devidos a infecção por hpv | |
| ES2526060T3 (es) | Péptido y tratamiento para la infección del VIH-1 | |
| WO2024187120A1 (en) | Formulations comprising stabilized sars-cov-2 peptides and uses thereof | |
| CY1112340T1 (el) | Πεπτιδια για την θεραπευτικη αγωγη καρκινου που συνδεεται με τον ιο ανθρωπινων θηλωματων (hpv) και αλλων επιθηλιακων ογκων | |
| Brabant et al. | A flavivirus protein M-derived peptide directly permeabilizes mitochondrial membranes, triggers cell death and reduces human tumor growth in nude mice | |
| Patil et al. | Unleashing the Antiviral Potential of Stapled Peptides: A New Frontier in Combating Human Neurotropic Viral Infections | |
| T Radulescu | From the RB tumor suppressor to MCR peptides | |
| RU2008152813A (ru) | Пептиды с антипролиферативной активностью | |
| JP2023503996A5 (es) | ||
| TH59183B (th) | เพพไทด์สำหรับการรักษามะเร็งที่เกี่ยวข้องกับแพพิลโลมาไวรัส (hpv) ของมนุษย์และเนื้องอกของเนื้อเยื่อบุผิวอื่น | |
| TH62586A (th) | เพพไทด์สำหรับการรักษามะเร็งที่เกี่ยวข้องกับแพพิลโลมาไวรัส (hpv) ของมนุษย์และเนื้องอกของเนื้อเยื่อบุผิวอื่น | |
| WO2019030367A8 (en) | Method for the synthesis of monoprotected bifunctional prodrugs and antibody drug conjugates based thereon as well as a method for preparing antibody drug conjugates | |
| WO2022215622A1 (ja) | ピロールイミダゾールポリアミド化合物を有効成分とするがん転移阻害剤 | |
| EA202091519A1 (ru) | БИЦИКЛИЧЕСКИЕ ПЕПТИДНЫЕ ЛИГАНДЫ, ОБЛАДАЮЩИЕ СПЕЦИФИЧНОСТЬЮ К EphA2 | |
| PE20160672A1 (es) | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento. |